Leinco Technologies’ methods for expediting recombinant protein and monoclonal antibody production may be a good economic decision in the preclinical discovery phase. It eliminates the expense and time associated with developing a stable cell line before the characteristics of the antibody are fully known. This method also allows evaluation of antibody panels before moving forward with the establishment of a stable cell line. High purity recombinant proteins and monoclonal antibodies are produced in a mammalian expression system allowing glycosylation and highly biologically active proteins with no need for refolding.
Expedited Expression of Human Monoclonal